F. Habersetzer

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Christophe Corpechot, Olivier Chazouillères, Antoine Rousseau et al. · Journal of Hepatology · 2017 · 46 citations

Medicine, Internal Medicine, Pharmacotherapy +12

1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS

Mark Sulkowski, M. Rodríguez‐Torres, E. Läwitz et al. · Journal of Hepatology · 2012 · 41 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION

Xavier Forns, M. Prieto, Michael Charlton et al. · Journal of Hepatology · 2014 · 37 citations

Medicine, Internal Medicine, Pharmacotherapy +10

P.384 Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug® (DT) for patients with advanced hepatocellular carcinoma (HCC)

Philippe Merle, Shahid Ahmed, F. Habersetzer et al. · Journal of Clinical Virology · 2006 · 19 citations

Pharmacy, Oncology, Pharmacology +14

Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC)

Philippe Merle, Shahid Ahmed, F. Habersetzer et al. · Journal of Clinical Oncology · 2006 · 18 citations

Pharmacy, Oncology, Pharmacology +17